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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYAccumulation of a-synuclein (a-syn) into insoluble aggregates occurs in several related disorders collectively referred to as synucleinopa-
thies. To date, studies have used neural stem cells (NSCs) to examine questions about a-syn propagation, but have overlooked the ther-
apeutic potential of NSC transplantation to modulate cognition in disorders such as dementia with Lewy bodies or Parkinson’s disease
dementia. Here, we show that striatal transplantation of NSCs into aged a-syn transgenic mice significantly improves performance in
multiple cognitive and motor domains. This recovery is associated with NSC expression of brain-derived neurotrophic factor (BDNF),
which restores depleted levels and modulates dopaminergic and glutamatergic systems. Most importantly, transplantation of BDNF-
depleted NSCs fails to improve behavior, whereas AAV-mediated BDNF delivery mimics the benefits of NSC transplantation, supporting
a critical role for this neurotrophin in functional improvement. Thus, NSC transplantation could offer a promising approach to treat the
understudied yet devastating cognitive components of many synucleinopathies.INTRODUCTION
Dementia with Lewy bodies (DLB) is the second most com-
moncauseofage-relateddementia, affectingover1.3million
people in the United States alone (Vann Jones and O’Brien,
2014). DLB is associated with the accumulation of insoluble
aggregates of the presynaptic protein a-syn within the cor-
tex, hippocampus, and brainstem that leads to progressive
neurodegenerationand impairments in cognitionand spon-
taneousmildparkinsonism(MayoandBordelon,2014).DLB
is closely related to a second disorder, Parkinson’s disease
(PD) dementia (PDD) that develops in up to 70% of PD pa-
tients (Dubois and Pillon, 1997; Marsh and Blurton-Jones,
2012). Current treatments for DLB and PDD are limited
and provide only modest symptomatic relief; thus, there is
a pressing need to identify new and effective therapies.
Unfortunately, the impact of stem cell transplantation in
models that develop a-syn pathologyhas thus far only been
examined in terms of cell-to-cell transmission of pathology
(Desplats et al., 2009; Hansen et al., 2011). In contrast,
many studies have demonstrated promising improvements
in motor function by transplanting dopaminergic (DAer-
gic) precursors in neurotoxin models of PD (Lees and
Smith, 1983; Docherty and Burn, 2010). However, cogni-
tive deficits in DLB/PDD are strongly associated with
a-syn and neurotoxin models fail to mimic this important
phenotype. It therefore remains critical to examine theStem Cell Rtherapeutic potential of stem cell transplantation in the
presence of a-syn pathology and to better understand the
impact of cell transplantation in models of DLB and PDD.
In this context, neural stem cells (NSCs), which can
migrate and produce high levels of neurotrophic factors,
may offer a promising alternative to DA precursor trans-
plantation. Here, we utilized a human a-syn-expressing
mouse model that recapitulates many of the salient fea-
tures of DLB/PDD, including the progressive development
of Lewy body pathology and significant cognitive dysfunc-
tion (Masliah et al., 2000; Amschl et al., 2013). Using these
mice, we investigated the migration and differentiation of
transplanted NSCs within the striatum and their impact on
behavior, a-syn pathology, and DAergic and glutamatergic
regulation. Our results reveal that NSC transplantation can
dramatically improve both motor and cognitive function
by elevating levels of brain-derived neurotrophic factor
(BDNF), a protein implicated in DLB/PDD cognitive im-
pairments (Leverenz et al., 2011). Pharmacological manip-
ulations implicate both DAergic and glutamatergic circuits
downstream of BDNF in this recovery. Furthermore,
shRNA-mediated loss-of-function studies confirm the ne-
cessity of BDNF in this process, and AAV-mediated gain-
of-function experiments demonstrate that BDNF can
mimic the benefits of NSC transplantation. Collectively,
our studies reveal that NSCs can improve both the motor
and cognitive symptoms of DLB/PDD in a progressiveeports j Vol. 5 j 791–804 j November 10, 2015 j ª2015 The Authors 791
transgenic model by elevating levels of BDNF and
enhancing DAergic and glutamatergic function.RESULTS
NSC Transplantation Rescues Both Motor and
Cognitive Deficits in a-Synuclein Transgenic Mice
In order to assess the impact of NSC transplantation on
h-a-syn-associated cognitive and motor dysfunction, we
stereotactically injected haplotype-matched murine NSCs
or vehicle bilaterally into 12-month-old h-a-syn overex-
pressing (ASO) mice or WT littermates (100,000 cells per
side). At this age, ASO mice exhibit widespread Lewy
body-like pathology as well as substantial motor and cogni-
tive impairments (Masliah et al., 2000; Amschl et al., 2013).
In order to achieve the greatest impact of transplantation
on both cognitive and motor systems that are altered
by a-syn accumulation, we targeted the dorsal striatum
(Figure 1A; see Supplemental Experimental Procedures),
widely known to be involved in learning and memory
and highly interconnected with multiple cortical regions.
We used previously characterized GFP-expressing NSCs
(Mizumoto et al., 2003; Blurton-Jones et al., 2009). At
1 month after transplantation, mice were habituated,
trained, and tested on three motor tasks and two cognitive
tasks, and engraftment was assessed.
As expected, vehicle-treated ASO (ASOV) mice showed
significant impairments in all three motor tasks compared
with vehicle-injected WTs (WTV). The ASOV mice took
twice as long to reorient before descending on the pole
task (Figure 1B; F (3, 18) = 3.9; ANOVA p = 0.03). Likewise,
ASOVmice fell of the Rotarod in half the time ofWTV con-
trols (Figure 1C; F(3, 18) = 9.5; ANOVA p = 0.0006) and ex-
hibited an 83% increase in foot faults in the beam traversal
task (Figure 1D; F(3, 18) = 12, ANOVA p = 0.0002). In
contrast, ASO mice that received NSC transplants (ASOC)
performed similarly to both WTV and NSC-injected WT
mice (WTC) in all three motor tasks, demonstrating that
NSC transplantation can dramatically improve motor
function in transgenic a-synuclein mice.
To examine cognition in a model with motor impair-
ments, it is critical to use tasks that are not heavily influ-
enced by motor function. We therefore utilized Novel
Object Recognition (NOR) and Novel Place Recognition
(NPR) tasks: low-stress paradigms that quantify the propor-
tion of time spent examining a novel object and provide
data on cortical-dependent and hippocampal-dependent
memory, respectively. All four groups were habituated,
trained, and tested following standard protocols (Supple-
mental Experimental Procedures). Twenty-four hours
after training, mice were exposed to a novel object or novel
object placement, and the discrimination ratio between792 Stem Cell Reports j Vol. 5 j 791–804 j November 10, 2015 j ª2015 Theexploration time of old and new objects was calculated. As
shown, ASOV mice exhibited significant impairments in
NORcomparedwithWTVandWTCgroups, demonstrating
that h-a-syn overexpression can model important aspects
of DLB/PDD-related cognitive impairment (Figure 1E;
F(3, 18) = 19.3; ANOVA p = 0.0001). Striatal transplantation
of NSCs dramatically improved performance in this
cortical-dependent task, as ASOC mice discriminated be-
tween novel and familiar objects to a greater degree than
either WTV or WTC mice, indicating not only a benefit,
but enhancement in this task. In the hippocampal-depen-
dent NPR task, ASOV mice again showed significant
impairments thatwere also rescued byNSC transplantation
(Figure 1F; F(3, 18) = 21; ANOVA p = 0.0001). Because we
found no differences in activity during training (data not
shown), this confirmed that h-a-syn expression and NSC
transplantation alter memory performance independent
of effects on motor function. Thus, we demonstrate that
NSC transplantation can rescue both motor and cognitive
deficits in a transgenic model of DLB/PDD.
NSCs Migrate throughout the Striatum and into the
Cortex but Do Not Reach the Hippocampus
To begin to decipher the mechanism by which GFP-NSC
transplantation ameliorates behavioral deficits, we exam-
ined the migration and differentiation of engrafted cells.
Confocal microscopy demonstrated that at 6 weeks
following transplantation GFP-NSCs had migrated
throughout the striatum (Figure 1G). A modest number
of cells were also observed within the motor and perirhinal
cortices and amygdala, and in a few animals, some cells
even reached the substantia nigra (data not shown). How-
ever, no GFP-NSCs were detected within the hippocampus
of any animals. Engrafted NSCs differentiated primarily
into astrocytes and immature oligodendrocytes, with
only a few cells exhibiting an early neuronal fate (Figures
1H, 1I, and S1). No examples of fully matured GFP/NeuN
double-labeled neurons were detected (Figure S1). Taken
together, these findings are consistent with previous re-
ports that murine NSCs predominantly acquire gliogenic
phenotypes when transplanted into non-neurogenic re-
gions and with other studies that utilized these postnatal
day 1-derived cells (Herrera et al., 1999; Yamasaki et al.,
2007; Blurton-Jones et al., 2009). Interestingly, no signifi-
cant differences in NSC differentiation were detected be-
tween ASO and WT transplanted mice (Figure 1I), and
each cell type migrated with similar distribution and dis-
tance from the injection site (Figure S1A). Finally, we exam-
ined markers of undifferentiated and proliferating cell
types, finding that a small number of NSCs that had
migrated beyond the dorsal striatum still expressed the
mitotic marker Ki67, or immature NSC markers Nestin or
Vimentin (Figures S2A–S2C).Authors
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Figure 1. NSC Transplantation Improves Both Motor and Cognitive Function in a-Synuclein Transgenic Mice
(A) a-Synuclein-overexpressing (ASO) and WT mice were aged to 12 months, and then syngeneic GFP-NSCs were transplanted bilaterally
into the striatum; 1 month later, motor and cognitive behavior were assessed.
(B–D) ASO vehicle treated controls (ASOV) show deficits in Pole reorientation (B), Rotarod performance (C), and beam traversal (D) tasks,
which were significantly ameliorated by NSC transplantation (ASOC).
(E and F) ASOV mice also showed significant deficits in cortical-dependent NOR (E) and hippocampal-dependent NPR (F), which were
improved by NSC transplantation (ASOC).
(G) GFP-NSCs (green) migrated from their medial striatal injection sites and engrafted predominantly within the striatum.
(H) The majority of NSCs differentiated into astrocytes (GFAP, red) and immature oligodendrocytes (Olig2, red). A smaller proportion of
NSCs adopted an early neuronal phenotype (DCX, red).
(I) No differences in NSC engraftment or differentiation were detected between WTC and ASOC groups.
(J) Immunohistochemical analysis also revealed no differences in either striatal h-a-syn inclusion number between ASOV and ASOC mice,
and no differences were detected in WT mice; Fisher’s PLSD post hoc WTV,WTCp < 0.003.
(K) Western blot analysis of striatal monomeric h-a-syn (Syn211) was not significantly altered by NSCs. Data are presented as mean ± SEM;
ANOVA p < 0.05 and Fisher’s PLSD post hoc *p < 0.0001 compared with all other groups (n = 6–8 mice/group).
Scale bar represents 100 mm (B) and 10 mm (C and D). See also Figures S1 and S2.
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Figure 2. NSC Transplantation Enhances Striatal BDNF Signaling with Downstream Effects on Dopamine and Glutamate Systems
(A and B) Western blots revealed that striatal BDNF was significantly decreased in ASOV mice but restored to WT levels by NSC
transplantation.
(C) Downstream of BDNF, phosphorylated Erk1was significantly elevated by transplantation (A and C).
(D) Transplanted cells continue to express BDNF, primarily within GFAP or Vimentin co-labeled astrocytic cells.
(E–G) Activated forms of TH (p-ser31 and p-ser19) were significantly decreased in ASOV mice and elevated by transplantation.
(H) The DA receptor type D2 was also decreased in ASOV mice and elevated in ASOC mice (E and H).
(legend continued on next page)
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Human a-Synuclein Pathology Is Not Altered by NSC
Transplantation
Previous studies have shown that reduction of a-syn can
improve motor function in a-syn transgenic mice (Masliah
et al., 2011). We therefore examined the effects of striatal
NSC transplantation on a -syn pathology in multiple brain
regions. Using a human-specific antibody, we first
confirmed that h-a-syn protein was expressed exclusively
in ASO mice. Interestingly, we found no effect of NSC
transplantation on h-a-syn, as both ASOV and ASOC
groups exhibited equivalent numbers of Lewy-body-like in-
clusions within the dorsal striatum (Figure 1J). Further
quantification of both detergent-soluble and insoluble
h-a-syn by western blot in the striatum (Figure 1K), hippo-
campus, perirhinal, motor and prefrontal cortices, and the
substantia nigra also confirmed that NSCs had no effect on
monomeric h-a-syn (Figures S3A–S3F). Likewise, mono-
meric a-syn phosphorylated at serine 129 (pS129), a path-
ological associated epitope, was also equivalent between
NSC and vehicle-injected ASO mice (post hoc Fishers’s
PLSD, p = 0.14; data not shown).
NSC-Induced Cognitive and Motor Improvements Are
Accompanied by Increased BDNF
Having found that NSCs had no impact on a-synuclein
pathology, we began to explore other potential mecha-
nisms that could be involved in NSC-mediated motor
and cognitive improvements. We previously showed that
these GFP-NSCs can produce high levels of specific growth
factors including BDNF (Blurton-Jones et al., 2009). West-
ern blot analysis revealed that striatal BDNF expression in
ASOV mice was half of that in WTV controls, but was fully
restored toWT levels in ASOCmice byNSC transplantation
(Figures 2A and 2B; F(3, 18) = 3.8; ANOVAp = 0.03). NSCs did
not increase BDNF inWTCmice, likely due to neurotrophic
self-regulatory mechanisms (Canossa et al., 1997; Bambah-
Mukku et al., 2014). Importantly, the BDNF receptor TrkB
was unaltered by either genotype or treatment (Figures
S3G and S3H), suggesting that increased BDNF could
readily influence behavior via the existing TrkB receptor
population. In contrast, no difference in expression of
glial-derived neurotrophic factor (GDNF; Figures S3G–S3J)
or its phosphorylated receptor RET were observed between
any treatment groups, indicating that changes in BDNF(I and J) Confocal optical densitometry confirmed significantly reduc
levels in ASOC mice.
(K and L) Striatal VGLUT-1 was also significantly decreased in ASOV m
(M) NSC transplantation also elevated striatal levels of GLT-1, but not
western blot graphs are presented as a percentage of WTV group. Fis
ASOVp < 0.01, WTC, ASOCp < 0.004 (n = 6–8 mice per group).
Scale bar represents 10 mm (D) and 30 mm (I).
Stem Cell Rspecifically play an important role in a-syn transgenic
mice. In addition to the detected changes in BDNF, phos-
phorylation of Erk1 (44 kDa), a major downstream effector
of BDNF signaling, was also increased by NSC transplanta-
tion in both ASOC and WTC mice (Figures 2A and 2C; F(3,
18) = 4.2; ANOVAp = 0.02).We confirmed that transplanted
NSCs continue to express BDNF primarily in cells co-ex-
pressing GFAP or vimentin (Figure 2D), suggesting that
glial-fated NSCs may contribute substantially to increasing
BDNF levels. Thus, NSC-mediated changes in BDNF appear
to influence growth and plasticity-associated signal trans-
duction within the striatum.
NSC Transplantation Alters Dopaminergic and
Glutamatergic Systems
To further understand the mechanism by which NSC-
derived BDNF ameliorates motor and cognitive behaviors,
we examined changes in expression of the rate-limiting
enzyme in DA synthesis, tyrosine hydroxylase (TH), as
well asmarkers of glutamate transport and regulation. First,
we utilized a well-established optical signal intensity anal-
ysis to examine TH terminals within the striatum (Fernagut
et al., 2007). As expected, we detected a significant reduc-
tion in TH-immunoreactive (TH-ir) terminals within
the dorsal striatum of ASOV mice relative to WTV controls
(Figures 2I, 2J, and S3K). More importantly, there was a sig-
nificant partial restoration of TH density in ASO mice that
received NSCs. In contrast, we confirmed as previously re-
ported that TH-ir neurons in the substantia nigra pars com-
pacta (SNpc)were not altered by h-a-syn in thismodel or by
NSC transplantation (Rockenstein et al., 2002) (Figure S3L).
To follow up on these findings, we performed biochemical
analysis of TH as well as two phospho-epitopes of TH
(serine-19 and serine-31) that are associated with increased
activity and dopamine production. Consistent with our
immunohistochemical data, TH phosphorylated at either
site was significantly increased in ASOC mice, suggesting
that NSCs elevate TH activity (Figures 2E–2G; F(3, 18) =
5.2; ANOVA p = 0.01). In further support of this effect,
expression of the DA receptor D2 was also significantly
increased with NSCs (Figures 2E and 2H; F(3, 18) = 6.4;
ANOVA p = 0.03). These data strongly suggest that NSC
transplantation enhances the function and signaling of
existing nigrostriatal DAergic neurons.ed expression of TH in ASOV striatum that was restored toward WT
ice and restored to WT levels by NSCs.
EAAC1 and GLAST (K and M). Data are presented as mean ± SEM. All
her’s PLSD post hoc *p < 0.03 compared with all other groups, WTV,
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Figure 3. BDNF Expression Correlates
with Both Motor and Cognitive Function,
whereas TH and GLT-1 Show Distinct As-
sociations with Motor and Cognitive
Function
BDNF, TH, and GLT-1 were compared with
cognitive (NPR) and motor (beam faults/
step) performance in ASO and ASOC mice.
BDNF was highly correlated with improve-
ments in both behaviors. However, while TH
was more closely correlated with motor
behavior, GLT-1 was more significantly
associated with cognitive function, sug-
gesting that dopaminergic and gluta-
matergic systems play key roles in motor and cognitive recovery respectively. Data points represent within-subject means of individual
animals p < 0.05. X axis, protein levels are represented as the percentage of WTV; y axis, beam faults/step are numerical ratios. NPR DI
values are discrimination index ratios (see Supplemental Experimental Procedures; n = 7 mice per group). See also Figure S3.We next examined the expression of glutamate trans-
porters within the striatum to determine whether a-syn
expression orNSC transplantationmight influence cortico-
striatal and hippocampal-striatal glutamatergic projec-
tions. BDNF is known to impact glutamate signaling and
activity to enhance plasticity (Gottmann et al., 2009),
and previous studies have strongly implicated glutamater-
gic dysfunction in PD (Greenamyre, 1993; Albin et al.,
1995); nevertheless, the potential therapeutic relevance
of glutamatergic systems to synucleinopathies and espe-
cially DLB/PDD-associated cognitive dysfunction has
been largely unexplored. Corticostriatal glutamatergic pro-
jections can be readily identified and examined via expres-
sion of vesicular glutamate transporter 1 (VGLUT-1).When
levels of VGLUT-1 within the dorsal striatum were quanti-
fied, we found a significant 35% decrease in ASOV mice
versus WTV controls. More importantly, this reduction
was restored to normal levels by NSC transplantation
(Figures 2K and 2L; F(3,18) = 3.3; ANOVA p = 0.04). In
contrast, thalamostriatal specific VGLUT-2 expression was
unchanged, suggesting NSCs have specific effect on corti-
costriatal glutamatergic systems (post hoc Fishers’s PLSD
p = 0.1, data not shown).
Another glutamate transporter implicated in PD is the
glial-specific transporter GLT-1 (Massie et al., 2010; Salva-
tore et al., 2012), which plays an important role inmultiple
aspects of neuronal plasticity and can be upregulated by
BDNF (Rodriguez-Kern et al., 2003; Pita-Almenar et al.,
2012). Although GLT-1 levels were unaltered between
WTV and ASOV groups, we found that NSC transplanta-
tion significantly increased GLT-1 expression in both
ASOC and WTC groups (Figures 2K and 2M; F(3,18) = 7.6;
ANOVA p = 0.002). By comparison, no changes were de-
tected in the two other glutamate transporters expressed
by both neurons and glia, EAAC1 or GLAST (Figure 2K).
Together these data show that corticostriatal glutamatergic796 Stem Cell Reports j Vol. 5 j 791–804 j November 10, 2015 j ª2015 Thesystems are indeed altered in a-syn transgenic mice and
that NSC transplantation can modulate astrocyte-depen-
dent corticostriatal glutamatergic systems.
Changes in BDNF, TH, and GLT-1 Correlate with
Distinct Improvements in Motor and Cognitive Tasks
The dramatic reduction in BDNF induced by h-a-syn
expression and the corresponding elevation of BDNF
following NSC transplantation suggest that this neurotro-
phin plays an important role in NSC-mediated behavioral
improvements. Supporting this hypothesis, striatal BDNF
expression in individual mice correlates well with NPR per-
formance (R2 = 0.48; p = 0.005) and inversely to beam
traversal faults (Figure 3; R2 = 0.60; p = 0.0001). Potentially
downstream of BDNF, TH expression is also correlated
strongly with beam traversal performance, but less so
with hippocampal-dependent NPR. Conversely, GLT-1
was significantly associated with NPR but showed a less
consistent association with beam traversal performance
(Figure 3). To further examine the potential divergent role
of these systems in motor and cognitive recovery we em-
ployed pharmacological loss-of function approaches using
the DA synthesis inhibitor a-methyl-p-tyrosine (aMT) and
GLT-1 inhibitor dihydrokainic acid (DHK). Safe and
optimal doses were determined by dose response studies
(Figure S4). A new set of ASO mice were then transplanted
with NSCs with or without co-treatment with aMT (ASOC-
aMT) or DHK (ASOC-DHK) (Figure 4A). At 1 month after
transplantation, behavioral testing was again performed.
In Rotarod and beam traversal motor tasks, aMT prevented
NSC-induced recovery; however, ASOC-DHK mice still ex-
hibited improved performance (Figures 4B and 4C; F(3, 20) =
9.6; ANOVA p = 0.0004; F(3, 20) = 3.9; ANOVA p = 0.03).
These data further support the notion that while TH phos-
phorylation is clearly necessary for NSC-mediated motor
improvements, changes in striatal glutamate reuptake viaAuthors
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Figure 4. TH and GLT-1 Function Are Necessary for NSC-Mediated Behavioral Improvements
(A) One group of ASOC mice received intraperitoneal DHK injections daily following a post-NSC-transplantation recovery period of 2 days
and continuing through behavioral testing. Another group of ASOC mice received the TH inhibitor a-methyl-p-tyrosine (ASOC-aMT) over
the ten days prior to and during behavioral assessment.
(B and C) aMT prevented NSC-mediated Rotarod (B) and beam traversal (C) recovery in ASOC mice; however, ASOC-DHK treated mice
displayed similar recovery of motor function to the ASOC group in both tasks.
(D) Conversely, in novel object recognition, NSC-mediated improvement was abolished by both aMT and DHK.
(E) NSC-mediated recovery in NOR was not inhibited by aMT, but was prevented by DHK.
(F–I) Striatal BDNF was increased by NSCs regardless of aMT or DHK treatment. TH levels were not significantly altered by NSCs and aMT
co-treatment; however, the activated form of TH (ser31) was reduced to ASOV levels by aMT despite NSC transplantation (F, H, and I). Data
presented as mean ± SEM. Western blot graphs presented as the percentage of ASOV group. Fisher’s PLSD post hoc ASOC, ASOC-DHKp < 0.02,
*p < 0.0004 compared with all other groups (n = 6–8 mice per group).
See also Figure S4.GLT-1 are not. Intriguingly, NSC-induced recovery of NOR
was blocked by both aMT and DHK treatments in ASOC
mice (Figure 4D; F(3, 20) = 13.3; ANOVA p = 0.0001), indi-
cating that both GLT-1 and TH activity are important for
NSC-mediated improvements in cortical-dependent mem-
ory. In contrast, while DHK prevented NSC-mediated im-
provements in NPR, aMT co-treatment had no effect on
this hippocampal-dependent task, as ASOC-aMTmice per-Stem Cell Rformed equivalently to saline-injected ASOC mice (Fig-
ure 4E; F(3, 20) = 8.2; ANOVA p = 0.009). Taken together,
these findings indicate that an NSC-induced increase in
GLT-1 is critical for bothNOR andNPR, but that NSC-medi-
atedDA regulation contributes primarily tomotor improve-
ments and NOR but not to hippocampal-dependent NPR.
Importantly, BDNF expression was unaltered by either
aMT or DHK treatments, remaining elevated in all threeeports j Vol. 5 j 791–804 j November 10, 2015 j ª2015 The Authors 797
NSC-transplanted groups (Figures 4F and 4G; F(3, 20) = 6.3;
ANOVA p = 0.004), suggesting that the observed changes
in DA and glutamate systems occur downstream of BDNF
signaling. In support of this, TH ser31 phosphorylation
was decreased similarly in both ASOV and ASOC-aMT
mice but remained elevated in saline- or DHK-injected
ASOC mice (Figures 4F, 4H, and 4I; F(3, 20) = 5.4; ANOVA
p = 0.007). These experiments further confirmed the
importance of NSC-induced changes in both DA and gluta-
mate systems and their role in NSC-mediated motor and
cognitive improvements. They also suggest that motor
dysfunction and NSC-mediated recovery are more closely
tied to DAergic systems, whereas cognitive tasks are more
influenced by NSC-mediated modulation of glutamatergic
systems, and that both of these behaviors are strongly
influenced by BDNF.
NSC-Derived BDNF Is Essential for Stem Cell-Induced
Cognitive and Motor Benefits
Given the strong correlations between striatal BDNF levels
and both motor and cognitive function, we hypothesized
that NSC-derived BDNF may be critical for NSC-mediated
improvements. We therefore employed a loss-of-function
approach to elucidate the role of BDNF in behavioral recov-
ery (Figure 5A). NSCs were stably modified to express a
shRNA targeting BDNF, leading to an 84% knockdown of
BDNF protein (Figure 5B). Importantly, the resulting
cells maintained multipotency as evidenced by unaltered
expression of the NSC markers Sox 2 and Musashi (Fig-
ure 5B). The effects of transplantation with BDNFshRNA-
NSCs (BKCs) or unaltered NSCs (NSCs) were then
examined in a new cohort of 12-month-old mice.
As in our initial experiments, transplantation of NSCs
increased the amount of time that ASO mice could stay
on the Rotarod in comparison to vehicle-injected ASO
mice. In contrast, transplantation with BKCs failed to
improve performance in ASO mice (Figure 5C; F(3,16) =
8.3, 5.6; ANOVA p = 0.006), indicating that NSC-derived
BDNF is essential for NSC-mediatedmotor recovery. Perfor-
mance on the beam traversal task further confirmed these
exciting findings, showing that BKCs could not reduce
the number of errors made by ASO mice (Figure 5D;
F(3,16) = 6.2; ANOVA p = 0.004). In NOR and NPR cognitive
tasks, both WTV and ASOC mice again showed significant
preference for the novel object or novel location equivalent
to that observed in our initial studies; nevertheless, trans-
plantation with BKCs failed to improve memory for either
the familiar object or location (Figures 5E and 5F; F(3,16) =
18.4; ANOVAp = 0.0001). These results clearly demonstrate
that NSC-derived BDNF is necessary for both themotor and
cognitive benefits of NSC transplantation.
Wenext performed biochemical analysis confirming that
striatal BDNF levels were indeed increased in ASOC mice798 Stem Cell Reports j Vol. 5 j 791–804 j November 10, 2015 j ª2015 Thebut not in ASO-BKC mice (Figures 5G and 5H; F(3,20) =
4.6; ANOVA p = 0.01). Likewise, striatal TH ser31 (F(3,20) =
4.4; ANOVA p = 0.02) and GLT-1 (F(3,20) = 1.7; ANOVA
p = 0.04) were elevated by transplantation of NSCs in
ASO mice, but were unchanged between ASOV and ASO-
BKC mice, demonstrating that NSC-derived BDNF plays
an important role in regulating DAergic and glutamatergic
neurotransmitter systems (Figures 5G, 5I, and 5J). Finally,
we confirmed that at 1 month following transplantation
NSCs continue to produce BDNF, whereas BKCs produce
far lower levels (Figure 5K), providing further evidence
that NSC-derived BDNF is necessary to elevate striatal
BDNF to behaviorally relevant levels. Together these results
strongly implicate the necessity of NSC-derived BDNF for
both the motor and cognitive benefits of NSC transplanta-
tion and the observed changes in DAergic and glutamater-
gic systems.
Viral Delivery of BDNF Mimics the Effects of NSCs
Having shown that NSC-derived BDNF expression is essen-
tial for both motor and cognitive behavioral recovery, we
next asked whether BDNF alone could provide a similar
benefit. Both ASO and WT mice received bilateral striatal
injections of either AAV2-mCherry or AAV2-mCherry-
BDNF (1 ml of 1.5 3 1013 viral particles/ml; Figures 6A
and 6B). Four weeks later, mice were subjected to the
same set of behavioral tasks (Figures 6C–6F). Similar to
NSC transplantation, AAV2-BDNF transduction improved
both Rotarod (Figure 6C; F(3,27) = 7.3, ANOVA p = 0.01)
and beam traversal performance (Figure 6D; F(3,27) = 7.8,
ANOVA p = 0.009) in ASO-BDNF mice compared with
ASO-mCherry mice, but had no effect in WT groups. In
the cognitive tasks, although AAV2-BDNF increased prefer-
ence for novel object and place in ASO-BDNF mice
compared with ASO-mCherry mice, overall differences be-
tween all four groups via ANOVA were not significant (Fig-
ures 6E and 6F; F(3,27) = 1.2, ANOVA p = 0.06). This suggests
that AAV-BDNF leads to similar motor behavioral recovery
to NSC-induced BDNF; however, cognitive function is not
as effectively restored.
To understand why AAV2-BDNF leads to similar motor
recovery as NSC-derived BDNF, but a diminished effect
on cognition, we examined striatal BDNF expression.
BDNF can undergo various forms of post-translational
modification, including phosphorylation and ATP-bind-
ing, which can in turn increase its biological activity (Ko¨nig
et al., 2008; Ferenz et al., 2012). Intriguingly, in addition to
the typical mature 14 kDA BDNF isoform observed in
mouse brain lysates, we also detected a second 12 kDa
BDNF band in AAV2-BDNF groups. As this lower band
may represent an alternatively processed or perhaps un-
phosphorylated form of BDNF, we analyzed both bands
individually. As expected, the 14 kDa BDNF band wasAuthors
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Figure 5. BDNF Is Necessary for NSC-Induced Motor and Cognitive Rescue
(A and B) A new cohort of ASO and WT mice aged to 12 months were injected bilaterally with either NSCs or BDNF shRNA knockdown NSCs
(BKCs); behavior was assessed as previously described. NSC BDNF expression was reduced 84% by shRNA in BKCs (p < 0.0001), and
multipotency was not affected by BDNF knockdown as measured by Sox2 and Musashi expression (B; n = 6 biological replicates).
(C and D) After four weeks, transplantation of BDNFshRNA -NSCs into ASO mice failed to improve either Rotarod (C) or beam traversal
performance (D).
(E and F) Similarly, NSC-derived BDNF was critical for NSC-mediated improvements in cognitive function in NOR and NPR tasks in ASO
mice (D–F).
(G–J) As in the ASOV group, striatal BDNF was not increased in ASO-BKC mice (G and H). BDNFshRNA -NSCs were also unable to significantly
increase striatal TH ser31 or GLT-1 expression (G, I, and J).
(K) In ASO mice, transplanted NSCs express BDNF (red), whereas BDNF is not detected in transplanted, BDNFshRNA-NSCs. Data presented as
mean ± SEM. Western blot graphs presented as % of WTV group. Fisher’s PLSD post hoc WTV, ASOCp < 0.04, WTVp < 0.02, ASOCp < 0.04 (n = 6–8
mice per group).decreased by 50% in ASO- mCherry mice compared with
the WT-mCherry group (Figures 6G and 6H; F(3,27) = 6.8,
ANOVA p = 0.02). Furthermore, AAV2-BDNF resulted in a
significant 37% increase in 14kDA BDNF levels in
ASO-AAV-BDNF mice. In contrast, analysis of the 12 kDa
band revealed a different pattern of expression, exhibiting
an over 5-fold increase in both AAV2-BDNF groups
versus AAV2-mCherry groups (Figures 6G and 6I; F(3,27) =
42.5, ANOVA p < 0.0001). Despite this high elevation ofStem Cell RBDNF by AAV transduction, there was no effect on mono-
meric h-a-syn expression (Figures 6G and 6J). In order to
determine why AAV2-BDNF was not able to significantly
restore cognitive function despite very high levels of
the 12 kDa BDNF, we compared expression levels directly
to NSC-transplanted ASO mice whose behavior was
fully rescued. Interestingly, we find that in contrast to
ASO-BDNF mice, NSC transplantation primarily increases
levels of the 14kDa BDNF protein (Figure 6K). Furthermore,eports j Vol. 5 j 791–804 j November 10, 2015 j ª2015 The Authors 799
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Figure 6. Viral Delivery of BDNF Partially Mimics the Effects of NSCs on Motor and Cognitive Function
(A) A new cohort of ASO and WT mice aged 12 months were bilaterally injected with either AAV2-mCherry-2A-BDNF or AAV2-mCherry.
(B) AAV2-BDNF expression at the injection site (scale bar represents 100 mm) and subcellular localization of BDNF (scale bar represents
10 mm) were verified by immunohistochemistry (B).
(C and D) AAV2-BDNF reversed motor deficits in ASO mice for both Rotarod (C) and beam traversal (D) tasks.
(E and F) In novel object and place recognition tasks, AAV2-BDNF modestly improved performance, although these effects were not
significant (E and F).
(G–J) Two bands representing mature BDNF were observed by western blot in AAV2-BDNF-treated mice (G). The 14 kDa band, which was
decreased in AAV2-mCherry-treated ASO mice, was significantly increased by AAV2-BDNF (G and H). The protein at 12 kDa was dramatically
increased by AAV2-BDNF expression in both WT and ASO mice (G and I). Monomeric h-a-syn (Syn211) was unaltered by AAV2-BDNF
expression (G and J).
(legend continued on next page)
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ASO-BDNF mice express modestly lower levels of the
14 kDa form and much higher levels of the 12kDa isoform
compared with ASO-NSCmice (Figures 6L and 6M; F(3,27) =
12.5, ANOVA p < 0.005).
Taken together, these data suggest that differences in
post-translational modification of BDNF provided by
NSCs versus AAV likely explain the shift from the typical
14 kDA endogenous BDNF signal to a predominant
12 kDa BDNF band in AAV-BDNF samples. The addition
of a single phosphorylation could for example readily shift
the electrophoretic mobility of a given protein by the
observed 2 kDa. These intriguing results could provide a
potential explanation for why AAV-mediated BDNF deliv-
ery leads to a less robust effect on cognition, although
future studies will clearly be needed to better understand
the influence of post-translational modifications on
BDNF-induced behavioral effects.DISCUSSION
Here we demonstrate that transplantation of NSCs can
dramatically improve both cognitive and motor function
in a progressive transgenic model of DLB/PDD. Interest-
ingly, the benefits occur without altering a-syn levels or
inclusion number, instead revealing a critical role for
BDNF-induced modulation of DAergic and glutamatergic
systems in both the disease process and NSC-mediated re-
covery. We also show that although viral delivery of
BDNF canmimic several outcomes of NSC transplantation,
NSCs provide a greater benefit to cognitive function, sug-
gesting that NSCs may be a more effective vehicle for
BDNF-dependent recovery. Together, these studies demon-
strate that transplantation of preferentially gliogenic NSCs
could offer a promising new therapeutic approach to treat
both the motor and understudied cognitive components
of synucleinopathies.
Currently approved therapies for DLB/PDD primarily
focus on strategies to replace or compensate for missing
DA via L-DOPA therapy or electrical modulation of DA
pathways (Bonelli et al., 2004; McKeith et al., 2005). While
these approaches can provide meaningful relief of motor
dysfunction, their effect on cognitive symptoms appears
to be marginal and inconsistent (Aarts et al., 2014; Robbins
and Cools, 2014) and may even accelerate global cognitive
decline (Kim et al., 2014). Although DLB can include DA
loss in the nigrostriatal pathway, it is modest (Colloby(K–M) Finally, BDNF expression levels were compared between ASO-
although not significantly lower levels of 14 kDa BDNF compared with
relative to NSCs (K and M). Data presented as mean ± SEM. Western
ASO-NSC (L and M). Fisher’s PLSD post hoc WT-BDNFp < 0.04, WT-BDNF,ASO
WT- Cherry, WT-BDNFp < 0.0004, ASO-BDNFp < 0.005, *p < 0.05 compared to
Stem Cell Ret al., 2012), and DA transporter binding does not correlate
to cognitive decline in DLB (Ziebell et al., 2013). This col-
lective evidence strongly argues for an alternative to DA
therapy for DLB that is catered toward the specific conse-
quences of synucleinopathy. The importance of a-synu-
clein in DLB/PDD is highlighted by the strong correlation
between a-syn accumulation and cognitive dysfunction
in patients (Halliday et al., 2014). Indeed, a recent report
confirmed that cerebrospinal fluid levels of a-syn correlates
well with cognitive decline, but not with motor dysfunc-
tion (Stewart et al., 2014). The testing and development
of treatments that could relieve the cognitive symptoms
of DLB/PDD therefore likely requires the use of models
that exhibit robust a-syn pathology with cognitive deficits,
such as the ASO model employed here.
Interestingly, BDNF has also previously been implicated
in the development of synucleinopathies. Specifically, hap-
losufficiency for the TrkB receptor results in nigral cell loss
and accumulation of a-syn in aged mice (von Bohlen und
Halbach et al., 2005). Changes in a-syn can in turn influ-
ence BDNF, as overexpression of WT a-syn in primary
neurons reduces BDNF production by suppressing the
transactivation of CREB and NFAT, two transcription fac-
tors that can regulate BDNF expression (Saha et al., 2000;
Yuan et al., 2010). It is likely that introduction of supple-
mental NSC or AAV2 derived BDNF was able to overcome
this deficiency despite the persistence of a-syn expression.
Although the ASO model does not exhibit substantial
neuronal loss, the correlations between DA and glutama-
tergic proteins and behavioral function suggest that ASO
mice nicelymodel the detrimental effects of a-syn accumu-
lation on these transmitter systems. Perhaps more remark-
able are the distinct associations of NSC-induced DA
changes with motor improvement and glutamatergic
changes with cognitive improvement (Figures 3 and 4).
In support of our findings, it was recently shown that stria-
tal DA transmission is disrupted in BDNF-deficient mice
(Bosse et al., 2012); thus, the reductions in TH and phos-
pho-TH that we observe in ASO mice are likely influenced
by the diminished levels of BDNF in these mice. In the
ASO model, changes in TH and phospho-TH induced by
NSC transplantation likely reflect an enhancement of ac-
tivity and function of existing nigrostriatal projections
that in turn improves behavior (Hyman et al., 1994; Siuciak
et al., 1996). Supporting this notion, pharmacological inhi-
bition of TH in the presence of NSC transplants prevented
NSC-induced motor and cortical-dependent cognitiveAAV-BDNF and ASO-NSC mice (K). AAV2-BDNF resulted in slightly
NSC transplantation (K and L) but a 500% increase in 12 kDa BDNF
blot graphs presented as a percentage of the WTV group (H–J) or
-Cherryp < 0.03, WT-BDNF,WT-Cherryp < 0.01, WT-Cherry, ASO-Cherryp < 0.005,
all other groups (n = 7–9 mice per group).
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benefits (Figure 4). Fascinatingly, NSC-mediated changes in
GLT-1 function were necessary for improvement in both
cortical- and hippocampal-dependent cognitive tasks, but
not motor performance. Although GLT-1 expression is
altered by NSC transplantation regardless of a-syn overex-
pression, this marker may indicate an increase in NSC-
derived astrocytes, which are in turn stimulated to produce
BDNF in ASO mice (Figure 2D). Deficiency of striatal
VGLUT-1 (Granseth et al., 2015) or GLT-1 (Hsu et al.,
2015) can both lead to cognitive deficits, further support-
ing the hypothesis that NSC-induced increases in these
transporters improves cognition. Finally, expression and
distribution of both VGLUT-1 (Melo et al., 2013) and
GLT-1 (Rodriguez-Kern et al., 2003) can be influenced by
BDNF, further substantiating an upstream effector role for
this neurotrophin in restoring balance to glutamate neuro-
transmission. The dissociation of the effects of NSCs on
DAergic and glutamatergic systems and motor and cogni-
tive function suggests that a balanced regulation of both
striatal DA and corticostriatal glutamate could be key to
rescuing a-syn-related deficits.
The necessity of BDNF in NSC-mediated behavioral
improvement in ASO mice is further confirmed by the
inability of BDNFshRNA-NSCs to rescue either motor or
cognitive function. In contrast, AAV2-BDNFmimics the ef-
fects of NSC transplantation on motor function and
partially improves cognitive function. The less striking
impact of AAV2-BDNF compared with NSC delivery may
be explained by differences in the post-translational modi-
fication of BDNF (Mowla et al., 2001; Ko¨nig et al., 2008;
Ferenz et al., 2012). Alternatively, it is plausible that addi-
tional NSC-derived factors might enhance the efficacy of
NSC transplantation (Redmond et al., 2007). In conclu-
sion, our data strongly suggest that striatal NSC transplan-
tation and the resulting elevation of BDNF could provide a
promising therapeutic approach to restore dopaminergic
and glutamatergic neurotransmission and motor and
cognitive function in in DLB/PDD.EXPERIMENTAL PROCEDURES
Animals, NSC Transplantation, AAV-BDNF Injection,
and Behavior
All procedures were performed in strict accordance with the UC
Irvine and NIH animal use regulations and were approved by an
institutional review board. Hemizygous ASOmice have been previ-
ously characterized and are maintained on a purebred C57B/6
background (Masliah et al., 2000). Hippocampal/cortical GFP-
NSCs were microdissected from syngeneic GFP-transgenic mice
at postnatal day 1, grown as adherent monolayers, and trans-
planted at passage 15 as previously described (Mizumoto et al.,
2003, Blurton-Jones et al., 2009). BDNFshRNA GFP-NSCs were also
generated via lentiviral delivery and stable selection of a shRNA802 Stem Cell Reports j Vol. 5 j 791–804 j November 10, 2015 j ª2015 Theconstruct targeting murine BDNF (Blurton-Jones et al., 2009).
Twelve-month-old ASO and WT mice were randomly assigned to
a treatment group and either vehicle, or 50,000 NSCs per site
(1 ml volume, two sites per side) were transplanted bilaterally
into the dorsal striatum (Bregma +0.03 AP, ±2.0 ML, 3.0 and
3.5 DV; Supplemental Experimental Procedures). For AAV exper-
iments, AAV2-mCherry or AAV-mCherry-2A-BDNF (Vector Bio-
labs) were injected bilaterally at the same striatal coordinates
(1 ml of 1.5 3 1013 viral particles/ml). Behavioral studies were per-
formed and analyzed blinded and examinedmotor function using
Rotarod, pole, and beam traversal tests, whereas cortical- and hip-
pocampal-dependent learning and memory were examined using
novel object and NPR, respectively (Supplemental Experimental
Procedures).
Biochemical, Histological, and Statistical Analyses
At 6 weeks after transplantation, mice were sacrificed by Euthasol
and transcardial perfusion (Supplemental Experimental Proce-
dures). For biochemical assessment, tissue was microdissected
from flash-frozen half brains; 40-mm sections of post-fixed half
brains were processed for immunohistochemistry and imaged via
confocal microscopy (Supplemental Experimental Procedures).
All animals were randomly assigned to treatment groups with
randomly generated identification codes to keep the researcher
blind throughout testing and analysis. Comparisons between
multiple groups utilized two-way ANOVA followed by Fisher’s
PLSD post hoc tests (Supplemental Experimental Procedures).
Figure asterisks denote significance difference from all other
groups; a significant difference from specific groups is denoted
with the name of that group in place of asterisks.
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